<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29838">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718261</url>
  </required_header>
  <id_info>
    <org_study_id>SIREN</org_study_id>
    <nct_id>NCT02718261</nct_id>
  </id_info>
  <brief_title>Sup-Icu RENal (SIREN)</brief_title>
  <acronym>SIREN</acronym>
  <official_title>Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SUP-ICU Principle investigator: Dr. M. Krag, Rigshospitalet, Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SUP-ICU Sponsor: Dr. M.H. Moller, Rigshospitalet, Copenhagen, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <brief_summary>
    <textblock>
      Data show that episodes of bleeding may often be observed in critically ill patients with
      dialysis-dependent acute renal failure (ARF) on renal replacement therapy (RRT). From a
      clinical perspective, patients with dialysis-dependent ARF and end-stage renal disease
      (ESRD) may be considered a high risk population in regard to e.g. development of
      gastrointestinal (GI-) bleeding.

      In the current prospective subanalysis &quot;SIREN&quot; of the randomized placebo-controlled clinical
      trial &quot;SUP-ICU&quot; (NCT02467621), the investigators seek to elucidate whether the subpopulation
      of critically ill patients with dialysis-dependent acute renal failure benefits from
      prophylactic treatment with a proton-pump-inhibitor such as pantoprazole.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of patients with clinically important gastrointestinal (GI)-bleeding episodes undergoing RRT therapy within the first 3 days following ICU admission (&quot;RRT group&quot;) vs. in patients without need for RRT during ICU stay (&quot;control group&quot;).</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of ICU patients with clinically important GI-bleeding episodes in &quot;ESRD&quot; vs. &quot;RRT group&quot; vs. RRT at any time during ICU stay vs. &quot;control group&quot; incl. analysis of verum/ placebo subgroups.</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients receiving interventions to stop GI-bleeding in &quot;RRT group&quot;, &quot;ESRD group&quot;, &quot;RRT at any time on the ICU group&quot;, and &quot;control group&quot;: incl. analysis of verum/ placebo subgroups.</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of GI bleeding events in &quot;RRT group&quot;, &quot;ESRD group&quot;, &quot;RRT at any time on the ICU group&quot;, and &quot;control group&quot;: incl. analysis of verum/ placebo subgroups.</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units of red blood cells (RBC) transfused on ICU in &quot;RRT group&quot;, &quot;ESRD group&quot;, &quot;RRT at any time on the ICU&quot; and &quot;control group&quot; incl. assessment of verum/ placebo subgroups.</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units of RBC transfused per day on ICU in &quot;RRT group&quot;, &quot;ESRD group&quot;, &quot;RRT at any time on the ICU&quot; and &quot;control group&quot; incl. assessment of verum/ placebo subgroups.</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of onset of pneumonia during ICU stay in &quot;RRT group&quot; vs. &quot;ESRD group&quot; vs. &quot;RRT at any time on the ICU&quot; vs. &quot;control group&quot; incl. analysis of verum/ placebo subgroups</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on treatment of Clostridium difficile enteritis in &quot;RRT group&quot; vs. &quot;ESRD group&quot; vs. &quot;RRT at any time on the ICU&quot; vs. &quot;control group&quot; incl. analysis of verum/ placebo subgroups</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay in &quot;RRT group&quot; vs. &quot;ESRD group&quot; vs. &quot;RRT at any time on the ICU&quot; vs. &quot;control group&quot; incl. analysis of verum/placebo subgroups</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day/360-day/ ICU mortality rate in &quot;RRT group&quot; vs. &quot;ESRD group&quot; vs. &quot;RRT at any time on the ICU&quot; vs. &quot;control group&quot; incl. analysis of verum/ placebo subgroups.</measure>
    <time_frame>90 day, 360 days, or length of ICU stay, as applicable</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Risk for clinically important GI-bleeding episodes in &quot;RRT group&quot;, &quot;ESRD group&quot;, &quot;RRT at any time on the ICU&quot;, and &quot;control group&quot; before the background of baseline disease severity/ demographics etc.</measure>
    <time_frame>90 days or length of ICU stay, as applicable</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3350</enrollment>
  <condition>Critical Illness</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Verum (pantoprazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <arm_group_label>Verum (pantoprazole)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9% (matching placebo)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  please refer to SUP-ICU (NCT02467621) trial

        Exclusion Criteria:

          -  please refer to SUP-ICU (NCT02467621) trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joerg C Schefold, MD</last_name>
    <phone>+41-31-6325397</phone>
    <email>joerg.schefold@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Krag, MD</last_name>
      <email>mette.krag.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care Medicine, University of Bern,</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.sup-icu.com</url>
    <description>Homepage SUP-ICU RCT</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>March 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Inselspital, Berne</investigator_affiliation>
    <investigator_full_name>JÃ¶rg Schefold</investigator_full_name>
    <investigator_title>SIREN principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>NCT02467621</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://clinicaltrials.gov/ct2/show/NCT02467621?term=SUP-ICU&amp;rank=1</doc_url>
      <doc_comment>SUP-ICU Website</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
